Company intelligence / Profile preview
Enceladus Pharmaceuticals
Naarden, North Holland, Netherlandsenceladus.nl ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Enceladus has developed Nanocort, a novel pharmaceutical for treatment of acute rheumatoid arthritis flares, which completed a Phase I/II investigator-led study. The company also has other liposomal corticosteroid formulations in development.
- Therapeutic areas
- GastroenterologyOncologyImmunologyCardiovascular
- Modalities
- Liposomal formulations of corticosteroids
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
GalapagosClinquest
Beyond the preview
Go deeper on Enceladus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enceladus Pharmaceuticals.